| 8.8 -0.045 (-0.51%) | 11-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.92 | 1-year : | 13.3 |
| Resists | First : | 10.2 | Second : | 11.39 |
| Pivot price | 9.08  |
|||
| Supports | First : | 8.3 | Second : | 6.9 |
| MAs | MA(5) : | 8.65  |
MA(20) : | 9.57 |
| MA(100) : | 10.03 |
MA(250) : | 9.7 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 14.9 |
D(3) : | 11.2 |
| RSI | RSI(14): 35.3 |
|||
| 52-week | High : | 21.95 | Low : | 0.48 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ FGEN ] has closed above bottom band by 43.9%. Bollinger Bands are 29.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.89 - 8.93 | 8.93 - 8.97 |
| Low: | 8.26 - 8.31 | 8.31 - 8.35 |
| Close: | 8.77 - 8.84 | 8.84 - 8.91 |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Wed, 12 Nov 2025
FibroGen, Inc. (NASDAQ:FGEN) Q3 2025 Earnings Call Transcript - Insider Monkey
Mon, 10 Nov 2025
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Mon, 10 Nov 2025
FibroGen Inc (FGEN) Q3 2025 Earnings Call Highlights: Strategic Moves Bolster Financial ... - Yahoo Finance
Fri, 07 Nov 2025
FibroGen Receives $6.4 Million Payment from AstraZeneca - The Globe and Mail
Mon, 03 Nov 2025
FibroGen (NASDAQ: FGEN) sets Q3 results; 5:00 PM ET conference call Monday - Stock Titan
Tue, 02 Sep 2025
$220M Deal: FibroGen Divests China Operations to AstraZeneca, Extends Cash Runway to 2028 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3.63e+006 (%) |
| Held by Institutions | 1.5 (%) |
| Shares Short | 112 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.704e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 2 % |
| Operating Margin | 598.8 % |
| Return on Assets (ttm) | -499.1 % |
| Return on Equity (ttm) | -11.9 % |
| Qtrly Rev. Growth | 8.3e+006 % |
| Gross Profit (p.s.) | -7.17 |
| Sales Per Share | 1.81 |
| EBITDA (p.s.) | -14.9 |
| Qtrly Earnings Growth | -12.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 4.88 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 104780 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|